{"entity":{"id":"hst-1011","kind":"drug","name":"HST-1011","aka":["CBL-B inhibitor"],"tldr":"HST-1011 is a small-molecule inhibitor from HotSpot Therapeutics, Inc, in registered phase 2 trials for metastatic cancer.","summary":"HST-1011 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by HotSpot Therapeutics, Inc, in metastatic cancer. Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of HST-1011","url":"https://clinicaltrials.gov/search?intr=HST-1011"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05662397"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"code":"HST-1011","modality":"Small-molecule inhibitor","mechanism":"Described in the registry record as a cbl-b inhibitor; the trial entries below carry the sponsor's wording.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/hst-1011/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"trial":[{"id":"nct05662397","kind":"trial","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","route":"/trials/nct05662397/"}]}}